Vastarel

Vastarel capsule What kind of merchandise is this exactly? In adults, trimetazidine is recommended for use as an add-on medication for the symptomatic treatment of patients with stable angina pectoris who are not well managed by first-line antianginal treatments or who are intolerant to these therapies. Instructions for Proper Usage and Dosage Dose is to be taken by mouth. One tablet of trimetazidine 35 mg should be taken twice daily, once in the morning and once in the evening, preferably with food. The recommended time to take the medication is during meals. When three months have passed, an evaluation of the benefits of the treatment should be performed, and trimetazidine should be stopped if there is no response to treatment. Individuals with renal impairment The suggested dosage for patients with moderate renal impairment (creatinine clearance [30-60] ml/min) is one tablet containing 35 mg to be taken in the morning with breakfast. Patients who are elderly It is possible for patients who are elderly to have greater trimetazidine exposure as a result of the age-related decline in renal function. Those who have mild renal impairment (creatinine clearance between 30 and 60 ml/min) should take one tablet of 35 mg in the morning while they eat breakfast. This is the suggested dosage. While working with senior individuals, it is important to proceed with caution when adjusting their dosage. There is insufficient evidence to determine if trimetazidine is both safe and effective for use in children younger than 18 years old (the paediatric population). No statistics are available. Overdosage About trimetazidine overdose, there is a lack of information currently accessible. The treatment should focus on relieving the symptoms. Contraindications Sensitivity to either the medication's active ingredient or any of the excipients that are stated in the Description. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other movement disorders associated to Parkinson disease are all included in this category. Renal impairment of a severe degree (creatinine clearance of less than 30 ml/min). Certain Safety Measures In most cases, it is best to avoid using this pharmaceutical medication if you are nursing. This pharmaceutical product is not indicated as an initial treatment for unstable angina, myocardial infarction, nor during the pre-hospital phase or during the first few days of hospitalization. Additionally, it is not a curative treatment for angina attacks, nor is it a treatment that can cure angina attacks. In the case of an angina episode, the coronaropathy ought to be reassessed, and a modification of the medication ought to be taken into consideration (medicinal treatment and possibly revascularisation). Trimetazidine has the potential to produce or exacerbate parkinsonian symptoms, such as tremor, akinesia, and hypertonia. These symptoms should be thoroughly evaluated on a frequent basis, particularly in older patients. Patients who have symptoms that raise questions about their neurological health should be referred to a neurologist for further evaluation. When movement abnormalities appear, such as parkinsonian symptoms, restless leg syndrome, tremors, or instability in gait, trimetazidine treatment should be discontinued permanently. These occurrences are uncommon and, in most cases, are treatable and reversible if the medication has stopped being used. After stopping their treatment with trimetazidine, the vast majority of patients reported feeling better within four months. If parkinsonian symptoms continue for more than four months after stopping treatment with a medicine, a second opinion from a neurologist should be obtained. It is possible for patients to experience falls as a result of gait instability or hypotension, in particular while they are receiving therapy for hypertension. When prescribing trimetazidine to patients who are expected to have an increased exposure, caution should be exercised. These patients include those with moderate renal impairment (for more information, see Pharmacology: Pharmacokinetics under Actions and Dosage & Administration), as well as elderly patients who are older than 75 years old (see Dosage & Administration). Trimetazidine does not show haemodynamic effects in clinical investigations; nonetheless, incidents of dizziness and sleepiness have been documented in post-marketing experience. These side effects may have an influence on a person's ability to drive or operate machinery. Usage During Pregnancy and During Breastfeeding Pregnancy: There are no data available from studies done on pregnant women who used trimetazidine. In investigations conducted on animals, there was no evidence of either direct or indirect negative effects in terms of reproductive toxicity. Avoiding the usage of trimetazidine while pregnant is the safest course of action to take because of the potential risks involved. It is not known if trimetazidine or any of its metabolites are excreted in human milk. If you are breastfeeding, you should know this. There is no way to rule out the possibility of danger to the neonates and infants. It is not recommended to take trimetazidine when a woman is nursing her child. Fertility: reproductive toxicity experiments conducted on rats of both sexes have showed no influence on the animals' ability to produce children.